Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.55 USD | -0.18% | +0.18% | +8.55% |
May. 16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
May. 16 | Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia | CI |
Evolution of the average Target Price on Axonics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Axonics, Inc.
Needham & Co. | |
Truist Securities | |
Leerink Partners | |
CL King | |
Piper Sandler | |
Wells Fargo Securities | |
Nephron Research | |
Wolfe Research | |
RBC Capital Markets | |
Morgan Stanley | |
Baird | |
KeyBanc Capital Markets | |
Mizuho Securities | |
Jefferies & Co. | |
BofA Securities | |
SVB Leerink | |
Barclays |
EPS Revisions
- Stock Market
- Equities
- AXNX Stock
- Consensus Axonics, Inc.